These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
252 related articles for article (PubMed ID: 35982054)
1. SARS-CoV-2 variants of concern: spike protein mutational analysis and epitope for broad neutralization. Mannar D; Saville JW; Sun Z; Zhu X; Marti MM; Srivastava SS; Berezuk AM; Zhou S; Tuttle KS; Sobolewski MD; Kim A; Treat BR; Da Silva Castanha PM; Jacobs JL; Barratt-Boyes SM; Mellors JW; Dimitrov DS; Li W; Subramaniam S Nat Commun; 2022 Aug; 13(1):4696. PubMed ID: 35982054 [TBL] [Abstract][Full Text] [Related]
2. Pre-Omicron Vaccine Breakthrough Infection Induces Superior Cross-Neutralization against SARS-CoV-2 Omicron BA.1 Compared to Infection Alone. da Silva ES; Kohnen M; Gilson G; Staub T; Arendt V; Hilger C; Servais JY; Charpentier E; Domingues O; Snoeck CJ; Ollert M; Seguin-Devaux C; Perez-Bercoff D Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887023 [TBL] [Abstract][Full Text] [Related]
3. Structural Study of SARS-CoV-2 Antibodies Identifies a Broad-Spectrum Antibody That Neutralizes the Omicron Variant by Disassembling the Spike Trimer. Zhan W; Tian X; Zhang X; Xing S; Song W; Liu Q; Hao A; Hu Y; Zhang M; Ying T; Chen Z; Lan F; Sun L J Virol; 2022 Aug; 96(16):e0048022. PubMed ID: 35924918 [TBL] [Abstract][Full Text] [Related]
4. Emergence of Multiple SARS-CoV-2 Antibody Escape Variants in an Immunocompromised Host Undergoing Convalescent Plasma Treatment. Chen L; Zody MC; Di Germanio C; Martinelli R; Mediavilla JR; Cunningham MH; Composto K; Chow KF; Kordalewska M; Corvelo A; Oschwald DM; Fennessey S; Zetkulic M; Dar S; Kramer Y; Mathema B; Germer S; Stone M; Simmons G; Busch MP; Maniatis T; Perlin DS; Kreiswirth BN mSphere; 2021 Aug; 6(4):e0048021. PubMed ID: 34431691 [TBL] [Abstract][Full Text] [Related]
5. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants. Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520 [TBL] [Abstract][Full Text] [Related]
6. The impact of spike N501Y mutation on neutralizing activity and RBD binding of SARS-CoV-2 convalescent serum. Lu L; Chu AW; Zhang RR; Chan WM; Ip JD; Tsoi HW; Chen LL; Cai JP; Lung DC; Tam AR; Yau YS; Kwan MY; To WK; Tsang OT; Lee LL; Yi H; Ip TC; Poon RW; Siu GK; Mok BW; Cheng VC; Chan KH; Yuen KY; Hung IF; To KK EBioMedicine; 2021 Sep; 71():103544. PubMed ID: 34419925 [TBL] [Abstract][Full Text] [Related]
7. A Combination of Receptor-Binding Domain and N-Terminal Domain Neutralizing Antibodies Limits the Generation of SARS-CoV-2 Spike Neutralization-Escape Mutants. Haslwanter D; Dieterle ME; Wec AZ; O'Brien CM; Sakharkar M; Florez C; Tong K; Rappazzo CG; Lasso G; Vergnolle O; Wirchnianski AS; Bortz RH; Laudermilch E; Fels JM; Mengotto A; Malonis RJ; Georgiev GI; Quiroz JA; Wrapp D; Wang N; Dye KE; Barnhill J; Dye JM; McLellan JS; Daily JP; Lai JR; Herbert AS; Walker LM; Chandran K; Jangra RK mBio; 2021 Oct; 12(5):e0247321. PubMed ID: 34607456 [TBL] [Abstract][Full Text] [Related]
8. Neutralization of Omicron sublineages and Deltacron SARS-CoV-2 by three doses of BNT162b2 vaccine or BA.1 infection. Kurhade C; Zou J; Xia H; Liu M; Yang Q; Cutler M; Cooper D; Muik A; Sahin U; Jansen KU; Ren P; Xie X; Swanson KA; Shi PY Emerg Microbes Infect; 2022 Dec; 11(1):1828-1832. PubMed ID: 35792746 [TBL] [Abstract][Full Text] [Related]
9. Molecular probes of spike ectodomain and its subdomains for SARS-CoV-2 variants, Alpha through Omicron. Teng IT; Nazzari AF; Choe M; Liu T; Oliveira de Souza M; Petrova Y; Tsybovsky Y; Wang S; Zhang B; Artamonov M; Madan B; Huang A; Lopez Acevedo SN; Pan X; Ruckwardt TJ; DeKosky BJ; Mascola JR; Misasi J; Sullivan NJ; Zhou T; Kwong PD PLoS One; 2022; 17(5):e0268767. PubMed ID: 35609088 [TBL] [Abstract][Full Text] [Related]
10. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Wang P; Nair MS; Liu L; Iketani S; Luo Y; Guo Y; Wang M; Yu J; Zhang B; Kwong PD; Graham BS; Mascola JR; Chang JY; Yin MT; Sobieszczyk M; Kyratsous CA; Shapiro L; Sheng Z; Huang Y; Ho DD Nature; 2021 May; 593(7857):130-135. PubMed ID: 33684923 [TBL] [Abstract][Full Text] [Related]
11. Identification of a highly conserved neutralizing epitope within the RBD region of diverse SARS-CoV-2 variants. Wang Y; Yan A; Song D; Duan M; Dong C; Chen J; Jiang Z; Gao Y; Rao M; Feng J; Zhang Z; Qi R; Ma X; Liu H; Yu B; Wang Q; Zong M; Jiao J; Xing P; Pan R; Li D; Xiao J; Sun J; Li Y; Zhang L; Shen Z; Sun B; Zhao Y; Zhang L; Dai J; Zhao J; Wang L; Dou C; Liu Z; Zhao J Nat Commun; 2024 Jan; 15(1):842. PubMed ID: 38287016 [TBL] [Abstract][Full Text] [Related]
12. Structural basis for potent antibody neutralization of SARS-CoV-2 variants including B.1.1.529. Zhou T; Wang L; Misasi J; Pegu A; Zhang Y; Harris DR; Olia AS; Talana CA; Yang ES; Chen M; Choe M; Shi W; Teng IT; Creanga A; Jenkins C; Leung K; Liu T; Stancofski ED; Stephens T; Zhang B; Tsybovsky Y; Graham BS; Mascola JR; Sullivan NJ; Kwong PD Science; 2022 Apr; 376(6591):eabn8897. PubMed ID: 35324257 [TBL] [Abstract][Full Text] [Related]
13. The neutralization potency of anti-SARS-CoV-2 therapeutic human monoclonal antibodies is retained against viral variants. Makdasi E; Zvi A; Alcalay R; Noy-Porat T; Peretz E; Mechaly A; Levy Y; Epstein E; Chitlaru T; Tennenhouse A; Aftalion M; Gur D; Paran N; Tamir H; Zimhony O; Weiss S; Mandelboim M; Mendelson E; Zuckerman N; Nemet I; Kliker L; Yitzhaki S; Shapira SC; Israely T; Fleishman SJ; Mazor O; Rosenfeld R Cell Rep; 2021 Sep; 36(10):109679. PubMed ID: 34464610 [TBL] [Abstract][Full Text] [Related]
17. Characterization of MW06, a human monoclonal antibody with cross-neutralization activity against both SARS-CoV-2 and SARS-CoV. Jiang W; Wang J; Jiao S; Gu C; Xu W; Chen B; Wang R; Chen H; Xie Y; Wang A; Li G; Zeng D; Zhang J; Zhang M; Wang S; Wang M; Gui X MAbs; 2021; 13(1):1953683. PubMed ID: 34313527 [TBL] [Abstract][Full Text] [Related]
18. Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75. Wang Q; Iketani S; Li Z; Guo Y; Yeh AY; Liu M; Yu J; Sheng Z; Huang Y; Liu L; Ho DD Cell Host Microbe; 2022 Nov; 30(11):1512-1517.e4. PubMed ID: 36108630 [TBL] [Abstract][Full Text] [Related]
19. Omicron BA.2 breakthrough infection enhances cross-neutralization of BA.2.12.1 and BA.4/BA.5. Muik A; Lui BG; Bacher M; Wallisch AK; Toker A; Finlayson A; Krüger K; Ozhelvaci O; Grikscheit K; Hoehl S; Ciesek S; Türeci Ö; Sahin U Sci Immunol; 2022 Nov; 7(77):eade2283. PubMed ID: 36125366 [TBL] [Abstract][Full Text] [Related]
20. Landscape of T cell epitopes displays hot mutations of SARS-CoV-2 variant spikes evading cellular immunity. Gan M; Cao J; Zhang Y; Fu H; Lin X; Ouyang Q; Xu X; Yuan Y; Fan X J Med Virol; 2024 Feb; 96(2):e29452. PubMed ID: 38314852 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]